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Bullous pemphigoid (BP) is a subepidermal blistering skin disorder 
of the elderly (1). Lesional skin of BP patients is characterized by a 
detachment of the basal keratinocytes of the epidermis from the der-
mis, resulting in tense, fluid-filled vesicles. Similar skin lesions were 
noted in herpes gestationis (HG), a nonviral disease of pregnancy (2). 
Immunofluorescence (IF) studies demonstrated that these patients 
exhibit circulating and tissue-bound autoantibodies directed against 
antigens of the basement membrane zone (BMZ) (3–8).
BP and HG autoantibodies recognize 2 antigens, BP230 and 
BP180, that are localized in the hemidesmosome, the main epi-
dermal structure involved in dermal-epidermal adhesion (4–6, 9). 
The BP230 antigen is restricted to the cytoplasmic plaque of the 
hemidesmosome and appears to interact directly with the inter-
mediate filament network (10, 11). The BP180 antigen is a type II 
transmembrane protein with an aminoterminal endodomain and 
an extended carboxyterminal ectodomain that spans the lamina 
lucida, projecting into the lamina densa of the BMZ (12–16). The 
ectodomain of human BP180 contains a series of 15 interrupted 
collagen domains (complement components 1–15 [C1–C15]) with 
the typical Gly-X-Y repeat (14). It has recently been shown that the 
BP180 extracellular domain forms a collagen triple helix (17, 18). 
The extracellular noncollagenous stretches are designated NC1 
(located at the carboxyl terminus) through NC16A (adjacent to 
the membrane-spanning domain). The NC16A domain of human 
BP180 harbors major extracellular antigenic sites recognized by BP 
and HG sera (19, 20).
Complement can be activated by 3 pathways: classical, lectin, and 
alternative. The classical pathway is activated primarily by antigen-
antibody complexes. The lectin pathway is activated by mannose-
binding lectin attachment to surface carbohydrates (such as on 
bacteria) and differs from the classical pathway only in this initial 
recognition and activation stage. The alternative pathway is activat-
ed continuously in the blood plasma by the spontaneous activation 
of C3, but this pathway is amplified to a significant level only in the 
presence of a molecular surface that supports the deposition, acti-
vation, and amplification of the alternative pathway complement 
proteins. Complement activation has been implicated in the patho-
genesis of BP and HG (21). Autoantibodies from BP and HG can fix 
complement in vitro and in vivo. C3 is often detected at the BMZ of 
the lesional/perilesional skin by direct IF (22, 23). Components of 
both the classical and the alternative complement pathways have 
been detected at the BMZ of patients’ skin, including C1q, C3, C4, 
C5, C5-9 (membrane attack complex, or MAC), factor B (Fb), factor 
H, and properdin (23–35). However, the relevance of any of these 
components, and which arm of the complement cascade (e.g., clas-
sical, lectin, or alternative) is involved in subepidermal blistering in 
BP and HG, remain unknown.
Our laboratory has developed an animal model of BP, which 
involves the injection of neonatal BALB/c mice with rabbit anti–
murine BP180 (anti-mBP180) antibodies (36). Subepidermal blis-
tering triggered by anti-mBP180 IgG depends on complement 
activation, mast cell (MC) degranulation, and polymorphonuclear 
neutrophil (PMN) infiltration (37–39). In this study, we investi-
gated the role of these 3 pathways of complement activation in the 
disease development of experimental BP by using mice genetically 
deficient in pathway-specific components. We found that the clas-
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sical and alternative pathways of complement system are required 
for experimental BP.
Results
Pathogenic anti-mBP180 antibodies induce subepidermal blisters in Fb–/–, but 
not C4–/–, mice.	To determine the roles of the classical and alternative 
complement activation pathways in subepidermal blister formation 
in experimental BP, WT, C4–/–, and Fb–/– mice (n = 12 per group) were 
injected with pathogenic anti-mBP180 IgG (2.6 mg/g body weight). 
WT and Fb–/– mice developed intense blisters (average clinical disease 
score, 2.7 for WT and 2.5 for Fb–/–; P = 0.175) 12 hours after patho-
genic IgG administration (Figure 1, A and I, and Table 1). Direct 
IF of perilesional skin of these mice showed in vivo deposition of 
pathogenic rabbit IgG (Figure 1, B and J) and murine C3 (Figure 1, 
C and K). H&E-stained skin sections from these mice revealed der-
mal-epidermal separation with PMN infiltration (Figure 1, D and L). 
In contrast, C4–/– mice exhibited no blisters 12 hours after injection 
with pathogenic IgG (Figure 1E). Direct IF of the skin of these mice 
showed in situ deposition of rabbit IgG (Figure 1F), but no murine 
C3 (Figure 1G), at the BMZ. Histologic examination of the skin of 
the C4–/– mice showed no signs of dermal-epidermal detachment 
(Figure 1H). Indirect IF demonstrated that the titers of circulating 
rabbit anti-mBP180 IgG in the C4–/– mice were comparable to those 
of the WT and Fb–/– mice (1:2,560 in 3 groups). These results dem-
onstrate that complement activation via the classical pathway but 
not the alternative pathway is essential for subepidermal blistering 
in experimental BP.
Inhibition of C1q abolishes experimental BP. Since C4–/– mice are 
impaired in both the classical and lectin pathways, we then induced 
experimental BP in the absence of the classical pathway. If experi-
mental BP depends on the classical pathway, then blocking C1q, 
the first component of the classical pathway, should block the skin 
disease. Our next set of experiments demonstrated this was the 
case. In vitro, anti-mC1q antibody blocked anti-mBP180–mediat-
ed deposition of C1q and C3 at the BMZ (Figure 2, A–D). In vivo, 
WT mice (n = 6) pretreated with anti-mC1q antibody followed by 
pathogenic anti-mBP180 IgG showed no complement activation 
in the skin and developed no skin lesions (Figure 2, E–J, and Table 
1). These data further implicated classical pathway activation as 
the major pathway in experimental BP.
The alternative pathway plays an accessory role in experimental BP. 
To determine whether the alternative pathway augments the 
Table 1
Role of the complement activation of different pathways in 
experimental BP
IgG injected Treatment n Mean disease activity
WT
R50 – 9 0.00 ± 0.00
R530 – 24 2.75 ± 0.10
R530 Anti-mC1q 8 0.10 ± 0.08A
R50 Compound 48/80 6 0.00 ± 0.00
C4–/–
R50 – 9 0.00 ± 0.00
R530 – 12 0.04 ± 0.04B
R50 Compound 48/80 6 0.00 ± 0.00
R530 Compound 48/80 6 3.00 ± 0.00
R530 PMNs 6 3.00 ± 0.00
R530 IL-8 6 3.00 ± 0.00
Fb–/–
R50 – 6 0.00 ± 0.00
R530 – 12 2.54 ± 0.10C
Neonatal WT, C4–/–, and Fb–/– mice were injected i.d. with control IgG 
R50 or pathogenic rabbit anti-mBP180 IgG R530 alone (2.64 mg/g body 
weight) or were additionally pretreated with anti-mC1q neutralizing anti-
body (5 μg/g body weight), treated with compound 48/80 (1 μg/g body 
weight i.d.), treated with PMN chemoattractant IL-8 (50 ng/g body weight 
i.d.), or administered purified mouse PMNs (5 × 105 cells in 50 μl PBS 
i.d.) from WT mice 2 hours after IgG injection. Animals were examined 
12 hours after IgG injection. Clinical disease severity (mean ± SEM) 
was scored as described in Methods and analyzed by paired Student’s 
t test. AP = 0.00001; BP = 0.0000001; CP = 0.175 versus anti-mBP180 
IgG–injected WT mice. Three to four independent experiments were 
performed per group.
Figure 1
Clinical, IF, and histological examination of neonatal WT, C4–/–, and 
Fb–/– mice injected with pathogenic anti-mBP180 IgG. Neonatal WT, 
C4–/–, and Fb–/– mice were injected i.d. with pathogenic rabbit anti-
mBP180 IgG R530 or control rabbit IgG R50 (2.64 mg/g body weight) 
and examined 12 hours after injection. The pathogenic IgG-injected 
WT (A) and Fb–/– (I) mice developed extensive epidermal disease. The 
skin of these animals showed linear deposition of rabbit IgG (B and 
J) and mouse C3 (C and K) at the BMZ by direct IF. (D and L) H&E-
stained sections from these mice showed a subepidermal vesicle with 
PMN infiltrate. (E) In contrast, anti-mBP180 IgG–injected C4–/– mice 
showed no clinical evidence of skin disease. Direct IF studies showed 
rabbit IgG (F), but no mouse C3 (G) deposition at the BMZ. (H) These 
animals showed no evidence of subepidermal vesiculation at the light 
microscopic level. Skin from mice injected with anti-mBP180 IgG was 
negative for BMZ staining with negative control antibody (FITC-conju-
gated goat anti-human IgG), and skin from mice injected with control 
rabbit IgG showed negative BMZ staining with FITC-conjugated goat 
anti-rabbit IgG and anti-mC3 IgG (data not shown). Four independent 
experiments were performed per group. Arrowheads denote sites of 
antibody labeling and basal keratinocytes. D, dermis; E, epidermis; V, 
vesicle. Magnification, ×200 (B–D, F–H, and J–L).
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classical pathway in experimental BP, we injected WT, C4–/–, and 
Fb–/– mice (n = 12 per group) with a suboptimal dose (2.0 mg/g 
body weight) of pathogenic antibody, with which the injected WT 
mice developed an average clinical disease score of 1.5 at 12 hours 
after injection. We also extended IgG incubation time beyond 12 
hours and up to 48 hours. WT mice injected with the suboptimal 
dose of pathogenic antibody developed clinical disease scores of 
1.5, 2.2, and 2.9 at 12, 24, and 48 hours, respectively (Figure 3A). 
The pathogenic IgG-injected Fb–/– mice developed clinical disease 
scores of 1.25 (P = 0.21), 1.75 (P = 0.04), and 2.1 (P = 0.007) at 12, 24, 
and 48 hours, respectively. The C4–/– mice showed no skin blisters 
at any time point (P < 0.001). These results suggest that the classi-
cal pathway plays a major role in the early phase of subepidermal 
blistering and in the later phase the classical pathway in concert 
with the alternative pathway cause full-scale BP skin lesions.
To further confirm this conclusion, we extended the time course 
up to 14 days and compared the disease severity between WT and 
Fb–/– mice (n = 5 per group). As expected, circulating levels of 
pathogenic IgG in WT and Fb–/– mice decreased as the mice grew 
bigger (Figure 3B). The WT group developed clinical disease scores 
of 2.5 ± 0.26, 1.6 ± 0.19, 0.6 ± 0.1, and 0 ± 0 on days 1, 3, 7, and 14, 
respectively, while the Fb–/– group developed clinical disease scores 
of 1.83 ± 0.26 (P = 0.04), 1.25 ± 0.17 (P = 0.20), 0.58 ± 0.08 (P = 0.90), 
and 0 ± 0 on days 1, 3, 7, and 14, respectively. Myeloperoxidase 
(MPO) activity assay revealed a significantly higher level of PMN 
infiltration in the WT group than in the Fb–/– group at 24 hours, 
but similar levels of PMN infiltration were seen on days 3, 7, and 
14 in the skin of the IgG-injected WT and Fb–/– mice (Figure 3C). 
We also injected WT and Fb–/– mice with a higher dose of patho-
genic IgG (3 mg/g body weight) and observed no difference in 
clinical disease score or skin MPO activity between these 2 groups 
of mice at all time points (data not shown).
MC degranulation is impaired in C4–/– mice injected with pathogenic 
anti-mBP180 antibodies. Complement activation generates comple-
ment fragments C3a and C5a, of which C5a can mediate PMN 
chemotaxis and both C3a and C5a can mediate MC degranulation 
(40). We then determined whether complement activation via the 
classical pathway was required for MC degranulation, PMN recruit-
ment, or both by quantifying MC degranulation and PMN infiltra-
tion. Neonatal WT, C4–/–, and Fb–/– mice were injected intradermally 
(i.d.) with the suboptimal and optimal doses of pathogenic IgG and 
examined at 2, 12, 24, and 48 hours after injection. At 2 hours, when 
MC degranulation triggered by pathogenic IgG reaches its peak 
(38), toluidine blue staining revealed extensive MC degranulation 
in the dermis of WT and Fb–/– mice (Figure 4, A and C). In contrast, 
C4–/– mice exhibited a minimal level of MC degranulation in the 
dermis (Figure 4B). Quantification of MC degranulation revealed 
a significant reduction in the number of degranulating MCs in 
C4–/– mice compared with WT and Fb–/– mice (Figure 4D). WT and 
Fb–/– mice showed similar levels of MC degranulation. Thus, MC 
degranulation triggered by anti-mBP180 IgG mainly depends on 
complement activation of the classical pathway.
MPO activity assays revealed a significant difference in PMN 
infiltration at the IgG injection sites between WT and C4–/– mice 
at all time points (Figure 5A). There was no difference statisti-
cally between WT and Fb–/– mice at 12 hours (P = 0.057), but 
significant differences were observed at 24 and 48 hours after 
IgG injection (Figure 5A). There was no difference in PMN infil-
tration between anti-mC1q–treated WT and C4–/– mice at 12 and 
24 hours, but there was a significant difference between these 
groups at 48 hours after injection (Figure 5B). However, anti-
mC1q antibody–treated Fb–/– mice showed a drastic reduction in 
PMN recruitment at all time points compared with anti-mC1q 
antibody–treated WT and C4–/– mice (Figure 5B). The degree of 
PMN recruitment in the anti-mC1q–treated Fb–/– mice was com-
patible to that previously shown in the pathogenic IgG–injected 
C5–/– mice (39), suggesting that the lectin pathway does not par-
ticipate in experimental BP. These results further substantiate 
the conclusion that the classical pathway plays a major role and 
the alternative pathway plays an accessory role in activating MCs, 
which in turn recruit PMNs to the dermal-epidermal junction, 
causing subepidermal blistering.
Figure 2
C1q inhibition. (A–D) In vitro C1q blocking. Neonatal mouse skin 
sections (5 μm) were incubated with pathogenic anti-mBP180 IgG 
followed by anti-mC1q or control antibody. Control IgG–treated skin 
sections showed C1q and C3 staining at BMZ (A and B), while anti-
mC1q–treated sections showed no C1q and C3 staining (C and D). 
(E–J) In vivo C1q blocking. Neonatal WT mice were pretreated with 
anti-mC1q or isotype control IgG (5 μg/g body weight), injected with 
pathogenic anti-mBP180 IgG (2.64 mg/g body weight), and examined 
12 hours after pathogenic IgG injection. (E) The control IgG–treated 
mice developed BP disease. (F and G) Direct IF showed deposition of 
rabbit IgG and mouse C3 at the BMZ. In contrast, mice pretreated with 
anti-mC1q antibody and injected with the same dose of pathogenic IgG 
showed no skin lesions (H), and direct IF exhibited the BMZ deposition 
of rabbit IgG (I) but not mouse C3 (J). Three independent experiments 
were performed per group. Magnification, ×200 (A–D, F, G, I, and J).
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C4–/– mice pretreated with a MC degranulating agent become susceptible 
to experimental BP. If the major role of complement activation in 
experimental BP is to activate MCs, then the requirement for the 
complement system for the subepidermal blistering in experimen-
tal BP should be bypassed by artificial induction of MC degranula-
tion. This is exactly what we found in the next set of experiments: 
C4–/– mice (n = 6) injected locally with compound 48/80, a potent 
MC degranulating agent, followed by pathogenic anti-mBP180 IgG 
developed clinical blisters to the same degree as the IgG-injected 
WT mice (Table 1). Like the diseased WT mice (Figure 6A), exten-
sive MC degranulation took place in the dermis of the compound 
48/80–treated C4–/– mice (Figure 6C). In contrast, C4–/– mice with-
out compound 48/80 treatment exhibited no skin lesions and 
minimal MC degranulation (Figure 6B). WT or C4–/– mice injected 
with compound 48/80 alone as a control exhibited MC degranu-
lation, but no skin lesions (Table 1). Quantification assays also 
revealed significantly elevated levels of MC degranulation (Figure 
6D) and PMN infiltration (Figure 6E) in compound 48/80–treated 
C4–/– mice relative to C4–/– mice without compound 48/80 pre-
treatment. These results further demonstrated that complement 
activation acts upstream of MC degranulation in the anti-mBP180 
IgG–induced inflammatory cascade.
Pathogenic anti-mBP180 IgG induces subepidermal blistering in C4–/– 
mice reconstituted with mouse PMNs or by i.d. injection of the PMN 
chemoattractant IL-8 Our findings indicate that a major function 
of complement activation in experimental BP is the activation of 
MCs. Since activated MCs degranulate, recruiting PMNs to the 
skin site in experimental BP, it is expected that artificially recruit-
ing PMNs from the circulation to the dermis of C4–/– mice should 
circumvent the requirement for both complement activation and 
MC degranulation for disease phenotype. C4–/– mice were injected 
with pathogenic IgG and then reconstituted with mouse PMN. 
The C4–/– mice reconstituted with 5 × 105 PMNs (n = 6) developed 
subepidermal blisters 12 hours after IgG injection (Figure 7 and 
Table 1). In addition, C4–/– mice (n = 6) given an i.d. injection of 
IL-8 prior to, or coincident with, the treatment with anti-mBP180 
IgG developed extensive blisters 12 hours later (Figure 7 and 
Table 1). Significantly higher levels of PMN infiltration were seen 
in the lesional skin of C4–/– mice with PMN reconstitution com-
pared with C4–/–mice without PMN reconstitution (Figure 7). The 
mean MPO activity levels in skin extracts of C4–/– mice injected 
with anti-mBP180 IgG plus IL-8 and anti-mBP180 plus PMN were 
1.31 ± 0.29 and 1.43 ± 0.36 OD460/mg protein, respectively, com-
pared with 0.47 ± 0.04 OD460/mg protein in the skin from the 
C4–/– mice injected with anti-mBP180 IgG alone (P < 0.01). Taken 
together, these results clearly demonstrate that complement 
activation via the classical pathway mainly participates in PMN 
recruitment by directly activating MCs in experimental BP.
Discussion
The aim of this paper was to investigate the role of the comple-
ment activation pathways in experimental BP. Mice genetically 
deficient in the classical pathway component C4 are resistant 
to experimental BP. Because C4–/– mice are impaired in both the 
classical and lectin pathways, we induced experimental BP in WT 
mice pretreated with anti-mC1q antibody. Anti-mC1q antibody 
treatment completely abolished subepidermal blistering. Since 
BP is an autoantibody-mediated disorder, and activation of the 
classical pathway by antibody is initiated by C1q, it is likely that 
the attenuation of the pathology observed in the C4–/– mice in 
experimental BP is due to the absence of the classical and not the 
lectin pathway. Mice deficient in the alternative pathway compo-
nent Fb that were injected with pathogenic antibodies developed 
a delayed and less intense disease phenotype in our 0- to 14-day 
time course study. These results demonstrate that an intact alter-
native pathway is necessary for the full development of the skin 
disease. Taken together, our data suggest that activation of the 
classical pathway is essential for disease development and that 
the alternative pathway acts in concert with the classical pathway 
in subepidermal blistering.
We should point out that under the current experimental condi-
tions the contribution of the alternative pathway to experimental 
BP might be underestimated and that the involvement of the lectin 
Figure 3
Time course of subepidermal blistering in C4–/– and Fb–/– mice. Neona-
tal WT, C4–/–, and Fb–/– mice were injected i.d. with a suboptimal dose 
of pathogenic rabbit anti-mBP180 R530 IgG (2.0 mg/g body weight). 
The animals were examined at 12, 24, 48 hours, and up to 14 days 
after IgG injection. (A) Clinical score. The IgG-injected mice were 
examined at 12, 24, and 48 hours after injection (n = 12 per group). 
Disease severity is expressed as mean clinical disease score ± SEM. 
Three independent experiments were performed per group. (B) ELISA. 
Levels of circulating anti-mBP180 IgG were quantified and expressed 
as relative OD readings. There were no significant differences between 
WT and Fb–/– mice at all time points. n = 6 per group. (C) MPO activ-
ity assay. PMN infiltration in WT and Fb–/– mice (n = 6 per group) was 
significantly different on day 1 (P = 0.04), but not on day 3 (P = 0.34), 
day 7 (P = 0.15), or day 14 (P = 0.74). *P < 0.05, §P < 0.001 versus WT 
at the respective time points.
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pathway cannot be totally excluded. Given the fact that the IgG pas-
sive transfer neonatal mouse model is limited to a single injection 
of pathogenic antibody and is relatively short term (0–14 days), it 
is important to develop an adult mouse model with on-going BP 
disease and to compare the disease severity in WT mice with that of 
mice deficient in different complement activation pathways.
Complement activation has long been implicated in the disease 
development of BP and HG based on the identification of com-
ponents of the classical and alternative pathways in perilesional 
sites and blister fluids (21). Using the BP mouse model, we previ-
ously demonstrated that complement activation is indeed a nec-
essary step in the process of subepidermal blistering triggered by 
anti-mBP180 antibodies (37). In the present study, we provide the 
first direct evidence to our knowledge that subepidermal blister 
formation induced by pathogenic anti-mBP180 IgG requires both 
classical and alternative pathways. Our results suggest that local 
activation of the complement cascade is a key step in the formation 
of skin lesions in BP as well as HG patients. We should note that 
the complement pathway activated is determined by the isotype, 
subclass, and species of antibody used to elicit the lesion. In experi-
mental BP, pathogenic rabbit anti-mBP180 IgG belongs to only 
one isotype and recognizes a single pathogenic epitope. In human 
BP, conversely, BP180-specific autoantibodies belong to IgG1, -2, 
-3, and -4 and IgE, and these BP autoantibodies target multiple 
epitopes. It is possible that the complement pathway activated by 
pathogenic autoantibodies and the relative contribution of differ-
ent pathways in human BP may not be the same as in experimen-
tal BP. Future studies using a new mouse model of BP induced by 
anti-mBP180 autoantibodies will address which Ig isotype and 
subclass(es) are pathogenic and which complement pathway(s) are 
activated by the pathogenic antibody.
We have previously shown that anti-mBP180–mediated comple-
ment activation is essential for PMN recruitment to the cutane-
ous BMZ (37, 38). One finding that demonstrated this link is that 
C5–/– mice injected i.d. with a PMN chemoattractant, either C5a or 
IL-8, became susceptible to the pathogenic effects of anti-mBP180 
IgG (39). These data were consistent with the hypothesis that com-
plement activation via the classical pathway triggered by an anti-
mBP180 immune complex results in the generation of C5a, which 
subsequently leads to dermal-epidermal detachment. Our present 
studies provide direct evidence to support this idea — an intact clas-
sical pathway arm is required for subepidermal blister formation 
triggered by complement-fixing anti-mBP180 IgG. Thus, the major 
function of the complement system in experimental BP might well 
be to generate C5a, which would function in recruiting PMNs to 
the cutaneous BMZ. C5a could carry out this role directly (by func-
tioning as a PMN chemoattractant itself), indirectly (by stimulat-
ing local cells to release proinflammatory mediators such as IL-8), 
or through a combination of these 2 mechanisms (40). Recently, 
we have shown that in experimental BP, MC degranulation, which 
leads to PMN recruitment, mainly depends on complement activa-
tion (38). Our present data further demonstrate that MC degranu-
lation and subsequent PMN infiltration triggered by pathogenic 
anti-mBP180 antibodies was severely impaired in mice deficient in 
the classical pathway component C4. Taken together, our findings 
clearly reveal that the major function of complement activation 
via the classical pathway is to directly activate MCs, which in turn 
recruit PMNs. Several recent studies have shown that the alterna-
tive pathway plays a key and, in most instances, obligate role in 
generating proinflammatory complement activation products in 
vivo (41). In experimental BP, the disease severity is significantly 
compromised without the alternative pathway. However, it is yet 
to be determined the exact role the alternative pathway plays in BP 
and how this pathway is activated.
In the K/BxN serum transfer model of inflammatory arthritis, 
the joint disease is triggered by anti–glucose-6-phosphate isom-
erase (anti-GPI) antibodies and, like experimental BP, depends on 
PMNs and MCs (42–44). Unlike experimental BP, this arthritis 
mouse model requires the alternative pathway, and the classical 
pathway is entirely dispensable (45). The difference in the comple-
ment pathway usage between these 2 animal models may be due 
to the difference in targeted antigens (BP180 versus GPI) and their 
presentation for antibody generation and binding. Alternatively, 
the isotype difference of pathogenic antibodies used may cause 
this discrepancy. In experimental BP, rabbit anti-mBP180 IgG 
mainly activates the classical pathway, while anti-GPI antibodies 
activate the alternative pathway, since the dominant isotype of the 
anti-GPI antibody in K/BxN mice is IgG1 and murine IgG1 is very 
poor at complement activation via the classical pathway (42).
In summary, we have demonstrated that complement activation 
via the classical and alternative pathways plays a critical role in 
subepidermal blister formation in experimental BP. These findings 
may shed new light on the pathogenic mechanisms responsible 
Figure 4
MC degranulation is impaired in C4–/– mice injected with pathogenic 
IgG. WT, C4–/–, and Fb–/– mice were injected with an optimal or subop-
timal dose (2.64 or 2.0 mg/g body weight, respectively) of pathogenic 
anti-mBP180 IgG or with control IgG (2.64 mg/g body weight) and 
examined for MC degranulation 2 hours after IgG injection (peak of 
MC degranulation; n = 12 per group). (A–C) Toluidine blue staining. 
WT (A) and Fb–/– (C) mice showed extensive MC degranulation in 
toluidine blue–stained skin sections. In contrast, C4–/– mice (B) exhib-
ited much less MC degranulation. Original magnification, ×400. (D) 
Quantification of MC degranulation. MCs in the dermis of the IgG-
injected skin biopsies were counted and classified as degranulated 
or normal (see Methods). Total MCs in 5 random fields were counted 
(mean, 34.58 ± 9.29), and percent MC degranulation was calculated 
as described in Methods. MC degranulation was significantly reduced 
in C4–/– mice at both suboptimal and optimal doses of pathogenic 
IgG compared with WT. There was no difference in MC degranula-
tion between WT and Fb–/– mice at suboptimal (P = 0.054) or optimal 
doses (P = 0.073). Three independent experiments were performed 
per group. §P < 0.001 versus WT at the respective time points.
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for BP and HG and other subepidermal blistering diseases with an 
autoimmune response to BP180 such as mucous membrane pem-
phigoid, pemphigoid gestationis, and lichen planus pemphigoides 
(9, 46, 47). These findings may lead to more effective management 
of these human autoimmune blistering diseases.
Methods
Laboratory animals. Breeding pairs of C57BL/6J WT mice and C57BL/6J 
C4–/– mice were purchased from The Jackson Laboratory. Fb–/– mice back-
crossed 10 generations with C57BL/6J were generated as described previ-
ously (48). The mice were maintained at the University of North Carolina 
at Chapel Hill Animal Center. Neonatal mice (24–36 hours old with body 
weights between 1.4 and 1.6 g) were used for passive transfer experiments. 
Animal care and animal experiments were approved by the Animal Care 
Committee at the University of North Carolina at Chapel Hill.
Preparation of pathogenic anti-mBP180 IgG. The preparation of recombinant 
mBP180 and the immunization of New Zealand White rabbits were per-
formed as previously described (36, 49, 50). The pathogenicity of these IgG 
preparations was tested by passive transfer experiments as described below. 
A pathogenic anti-mBP180 IgG preparation (R530) and a nonpathogenic 
control IgG preparation (R50) were used in this study (39).
Induction of experimental BP and clinical evaluation of animals. Neonates were 
given on the back 1 i.d. injection of a sterile solution of IgG in PBS (50 μl 
IgG, 2.64 mg IgG/g body weight) as described previously (36). The site of 
the 50-μl injection, approximately 3–4 mm in diameter, was marked with 
ink. The skin at the IgG injection sites of the mice from the test and con-
trol groups was examined at different time points after the IgG injection. 
For the 0- to 3-day time course experiments, neonatal mice were injected 
and placed in a temperature- and humidity-controlled incubator. To keep 
neonatal mice alive for longer than 3 days, the neonatal mice were returned 
to their cages immediately after injection. The extent of cutaneous disease 
was scored as follows: 0, no detectable skin disease; 1, mild erythematous 
reaction with no evidence of the epidermal detachment sign (elicited by 
gentle friction of the mouse skin; when positive, this produced fine, per-
sistent wrinkling of the epidermis); 2, intense erythema and epidermal 
detachment sign involving 10%–50% of the epidermis in localized areas; 
3, intense erythema with frank epidermal detachment sign involving more 
than 50% of the epidermis in the injection site.
After clinical examination the animals were sacrificed, and skin and 
serum specimens were obtained. Each skin section (approximately 6 × 6 
mm in size) was cut into 3 pieces from the central lines: one (approximately 
3 × 3 mm) for routine histological examination by light microscopy (H&E 
staining) to localize the lesional site and PMN infiltration and toluidine 
blue staining to quantify MCs and MC degranulation, one (approximately 
3 × 3 mm) for direct IF assays to detect rabbit IgG and mouse C3 deposition 
at the BMZ, and one (approximately 3 × 6 mm) for MPO enzymatic assay 
to quantify the PMN accumulation at the skin injection site as described 
below. The sera of injected animals were tested by indirect IF techniques to 
determine the titers of rabbit anti-mBP180 antibodies using mouse skin 
cryosections as the substrate. Direct and indirect IF studies were performed 
as previously described (36) using commercially available FITC-conjugated 
goat anti-rabbit IgG (Kirkegaard & Perry Laboratories Inc.). Monospecific 
goat anti-mC3 IgG was purchased from Cappel Laboratories.
Inhibition of C1q in vitro and in vivo. For in vitro C1q inhibition, neona-
tal mouse skin sections were incubated with purified rabbit anti-mBP180 
or control IgG for 1 hour, after which freshly prepared mouse serum was 
added as a complete complement source in the presence of purified rat 
anti-mC1q monoclonal antibody or rat isotype control IgG1κ. After 1 hour 
of incubation, in situ deposition of mouse C1q and mouse C3 at the BMZ 
were detected with FITC-conjugated rat anti-mC1q monoclonal antibody 
and FITC-conjugated monospecific goat anti-mC3 antibody, respectively. 
For in vivo C1q inhibition, neonatal C57BL/6J mice were injected i.d. with 
5 μg purified rat anti-mC1q monoclonal antibody or isotype control rat 
IgG1κ. Two hours later, the mice were injected i.d. with pathogenic anti-
mBP180 IgG (2.64 mg/g body weight) and then examined 12, 24, and 48 
hours after pathogenic IgG injection as described above. Purified rat anti-
Figure 5
Relative contribution of the classical and alternative pathways of com-
plement in anti-mBP180–induced subepidermal blister formation. WT, 
C4–/–, and Fb–/– mice (n = 12 per group) were injected with an opti-
mal or suboptimal dose (2.64 or 2.0 mg/g body weight, respectively) 
of pathogenic anti-mBP180 IgG or with control IgG (2.64 mg/g body 
weight) in the absence (A) or presence (B) of anti-mC1q monoclonal 
antibody and examined at 12, 24, and 48 hours after IgG injection. 
Disease severity was quantified by measuring tissue MPO activities 
(mean + SEM) in the injection sites as an indicator of PMN recruitment. 
(A) Without C1q inhibition, significant reduction of PMN infiltration was 
seen in the skin of C4–/– mice at all time points and in Fb–/– mice at 
24 and 48 hours compared with WT mice. §P < 0.001. (B) Anti-mC1q 
antibody treatment significantly reduced PMN infiltration in all 3 strains 
of mice. C1q blocking caused a further significant reduction in PMN 
infiltration in Fb–/– mice relative to C4–/– and WT mice. Levels of PMN 
infiltration between anti-mC1q–treated WT and C4–/– mice were simi-
lar at 12 and 24 hours, but different at 48 hours. Three independent 
experiments were performed per group. *P < 0.05, §P < 0.001 versus 
WT at the respective time points. #P < 0.05 versus C4–/– at the respec-
tive time points.
research article
2898	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 116   Number 11   November 2006
mC1q monoclonal antibody and rat IgG1κ isotypic control were purchased 
from Cedarlane Laboratories Ltd.
Quantification of MCs and MC degranulation. Skin sections (approxi-
mately 3 × 3 mm) of IgG-injected mice were fixed in 10% formalin. Par-
affin sections (6 μm thick) were prepared and stained with toluidine 
blue and H&E. Dermal MCs were counted by 2 individuals in the labo-
ratory in a blinded fashion and classified as degranulated (>10% of the 
granules exhibiting fusion or discharge) or normal in 5 random fields 
under a light microscope at ×400 magnification (38, 51). There was 
no significant difference between the 2 individual countings (for total 
MCs, 32.20 ± 6.52 versus 36.97 ± 11.55; P = 0.082). MCs with complete 
degranulation that may be missed by toluidine blue staining were iden-
tified by indirect IF with FITC-conjugated rat anti-mouse c-kit mono-
clonal antibody (BD Biosciences). Results were expressed as percentage 
of degranulated MC (number of degranulating MCs per total number 
of MCs in 5 random fields × 100%).
Quantification of PMN accumulation at antibody injection sites. Tissue MPO 
activity was used as an indicator of PMNs within skin samples of experi-
mental animals as described elsewhere (52). We previously showed that 
clinical skin blistering is directly correlated with the number of infiltrating 
PMNs in the IgG injection site (39). The mouse skin samples (approximately 
3 × 6 mm) were extracted by homogenization in 500 μl extraction buffer. 
MPO content was expressed as relative MPO activity (OD460/mg protein).
In vivo stimulation of MC degranulation. To stimulate MC degranulation, 
neonatal C4–/– mice were injected i.d. with compound 48/80 (1 μg/g body 
weight; Sigma-Aldrich), a MC degranulating agent. Skin MC degranula-
tion was analyzed by toluidine blue staining, and skin PMN infiltration 
was quantified by MPO assay.
Isolation and i.d. injection of PMNs Mouse PMNs were isolated from hepa-
rinized blood by dextran sedimentation followed by separation on a den-
sity gradient as described previously (53). PMN purity of the final cell 
preparation was consistently >96% as determined by cell-cytospin and 
LeukoStat staining (Fisher Scientific). The viability of the PMNs was >96% 
as determined by trypan blue exclusion. C4–/– mice were injected i.d. with 
pathogenic anti-mBP180 IgG (2.64 mg/g body weight in 50 μl PBS). Two 
Figure 6
Effect of MC degranulating agent on PMN infiltration and subepidermal 
blistering in pathogenic IgG–injected C4–/– mice. WT and C4–/– mice 
were injected with pathogenic anti-mBP180 R530 IgG (2.6 mg/g body 
weight) with or without pretreatment of the MC degranulating agent 
compound 48/80 (C48/80) and were examined 2 hours (for toluidine 
blue staining) and 12 hours (for clinical examination and MPO assay) 
after IgG injection. (A–C) Clinical examination and toluidine blue stain-
ing of the mouse skin showed subepidermal blisters and MC degranu-
lation in WT (A) and C4–/– mice with compound 48/80 pretreatment (C). 
(B) In contrast, C4–/– mice without compound 48/80 treatment exhibited 
no skin lesions and minimal MC degranulation. (D) MCs in the dermis of 
the skin were counted and classified as degranulated or normal. Total 
MCs in 5 random fields were counted (mean, 31.72 ± 8.41), and per-
cent MC degranulation was calculated. As expected, MC degranulation 
was significantly reduced in C4–/– mice compared with WT mice. How-
ever, a significant increase of MC degranulation was seen in the skin of 
compound 48/80–treated C4–/– mice. n = 6 per group. (E) MPO activity 
assay revealed significantly higher levels of PMN infiltration in WT and 
C4–/– mice with compound 48/80 pretreatment than those without it. Tis-
sue MPO activity at the injection sites was expressed as relative MPO 
activity. Three independent experiments were performed per group. 
n = 6 per group. **P < 0.01 versus WT and pretreated C4–/– mice.
Figure 7
In vivo reconstitution of PMNs at the tissue site restores experimental 
BP in C4–/– mice. C4–/– mice were injected i.d. with pathogenic anti-
mBP180 R530 IgG alone or in conjunction with IL-8 (50 ng/injection) 
or PMNs (5 × 105 cells) and were examined 12 hours after IgG injec-
tion. MPO activity assay showed significantly higher levels of PMN 
recruitment in the lesional skin of WT mice injected with pathogenic 
IgG, C4–/– mice coinjected with IL-8, and C4–/– mice coinjected with 
PMNs compared with C4–/– mice injected with pathogenic IgG alone 
as well as the nonlesional skin of WT and C4–/– mice injected with con-
trol IgG. Tissue MPO activity at the injection sites was expressed as 
relative MPO activity. Three independent experiments were performed 
per group. n = 6 per group. **P < 0.01 versus C4–/– mice injected with 
pathogenic IgG alone; Student’s t test for paired samples.
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hours later, these mice were injected with 5 × 105 PMNs i.d. at the same 
site (54, 55). The animals were analyzed 12 hours after the IgG injections 
as described above.
IL-8 pretreatment of C4–/– mice. A single i.d. injection of recombinant 
human IL-8 (50 ng in 50 μl PBS; R&D Systems) or an equivalent amount 
of BSA was given to neonatal C4–/– mice, followed by i.d. injection of rabbit 
anti-mBP180 IgG (2.64 mg/g body weight in 50 μl PBS) 1 hour later (39). 
Control animals received an equivalent amount of normal rabbit IgG in 
place of the anti-mBP180 IgG. The animals were analyzed 12 hours after 
the IgG injections as described above.
Statistical analysis. Data were expressed as mean ± SEM and were analyzed 
using Student’s t test (SigmaPlot; Systat). A P value less than 0.05 was con-
sidered significant.
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